Critical comparison of BMD and TD methods for the calculation of acceptable intakes for N-nitroso compounds.

The tumorigenic dose 50 (TD) is a widely used measure of carcinogenic potency which has historically been used to determine acceptable intake limits for carcinogenic compounds. Although broadly used, the TD model was not designed to account for important biological factors such as DNA repair and cell compensatory mechanisms, changes in absorption, etc., leading to the development of benchmark dose (BMD) approaches, which use more flexible dose-response models that are better able to account for these processes.

Complications of Nonsurgical Rhinoplasty with Hyaluronic Acid Injections: A Narrative Review.

Background: The increasing popularity of cosmetic procedures has led to a rise in both surgical and nonsurgical interventions. Rhinoplasty, particularly nonsurgical rhinoplasty using injectable fillers such as hyaluronic acid (HA), has become highly sought after due to its minimally invasive nature. Despite its benefits, complications can occur, ranging from minor to severe.

The Association between All-cause Mortality and Obstructive Sleep Apnea in Adults: A U-Shaped Curve.

Rationale And Objectives: The relationship between Sleep Apnea (SA) and mortality remains a topic of debate. We explored the relationship between the severity of SA and mortality and the effect of age on this association.

Methods: Using a Veterans' database, we extracted the apnea-hypopnea index (AHI) from physician interpretation of sleep studies, by developing a Natural Language Processing (NLP) pipeline (with 944 manually annotated notes) which achieved more than 85% accuracy.

Continuous glucose monitoring among adults with type 2 diabetes receiving noninsulin or basal insulin therapy in primary care.

Rates of type 2 diabetes (T2D) continue to rise in the United States, with many patients failing to achieve glycemic targets. Primary care providers often serve as the sole clinician managing diabetes. Continuous glucose monitors (CGMs) have shown promise in diabetes management, yet their adoption in primary care settings, especially among patients with T2D not using intensive insulin therapy, remains limited.